This is a repository copy of *Pathophysiology and diagnosis of pulmonary hypertension due to left heart disease*.

White Rose Research Online URL for this paper:
http://eprints.whiterose.ac.uk/157272/

Version: Published Version

**Article:**
Charalampopoulos, A., Lewis, R., Hickey, P. orcid.org/0000-0002-4683-7696 et al. (5 more authors) (2018) Pathophysiology and diagnosis of pulmonary hypertension due to left heart disease. Frontiers in Medicine, 5. 174.

https://doi.org/10.3389/fmed.2018.00174

**Reuse**
This article is distributed under the terms of the Creative Commons Attribution (CC BY) licence. This licence allows you to distribute, remix, tweak, and build upon the work, even commercially, as long as you credit the authors for the original work. More information and the full terms of the licence here:
https://creativecommons.org/licenses/

**Takedown**
If you consider content in White Rose Research Online to be in breach of UK law, please notify us by emailing eprints@whiterose.ac.uk including the URL of the record and the reason for the withdrawal request.
Pathophysiology and Diagnosis of Pulmonary Hypertension Due to Left Heart Disease

Athanasios Charalampopoulos*, Robert Lewis, Peter Hickey, Charlotte Durrington, Charlie Elliot, Robin Condliffe, Ian Sabroe and David G. Kiely

Sheffield Pulmonary Vascular Disease Unit, Royal Hallamshire Hospital, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, United Kingdom

Pulmonary hypertension due to left heart disease (PH-LHD) is the most common type of pulmonary hypertension, although an accurate prevalence is challenging. PH-LHD includes PH due to systolic or diastolic left ventricular dysfunction, mitral or aortic valve disease and congenital left heart disease. In recent years a new and distinct phenotype of “combined post-capillary and pre-capillary PH,” based on diastolic pulmonary gradient and pulmonary vascular resistance, has been recognized. The roles of right ventricular dysfunction and pulmonary vascular compliance in PH-LHD have also been elucidated recently and they appear to have significant clinical implications. Echocardiography continues to play a seminal role in diagnosis of PH-LHD and heart failure with preserved LV ejection fraction, as it can identify valve disease and help to distinguish PH-LHD from pre-capillary PH. Right, and occasionally left heart catheterization, remains the gold-standard for diagnosis and phenotyping of PH-LHD, although Cardiac Magnetic Resonance Imaging is emerging as a useful alternative tool in non-invasive diagnostic and prognostic assessment of PH-LHD. In this review, the latest evidence for more recent advances will be discussed, including the role of fluid challenge and exercise during cardiac catheterization to unravel occult post-capillary and the role of vasoreactivity testing. The use of many or all of these diagnostic techniques will undoubtedly provide key information about sub-groups of patients with PH-LHD that might benefit from medical therapy previously considered to be only suitable for pulmonary arterial hypertension.

Keywords: pulmonary hypertension, left heart disease, heart failure with preserved ejection fraction, left ventricular diastolic dysfunction, right heart catheterization

INTRODUCTION

Pulmonary hypertension due to left heart disease (PH-LHD) is the most common type of pulmonary hypertension (PH). The prevalence of PH in patients with heart failure varies significantly with diagnostic criteria from 25 to 83% (1–4). PH-LHD is defined by post-capillary hemodynamics at right heart catheterization (RHC); that is a mean pulmonary arterial pressure ≥25 mmHg and a mean pulmonary arterial wedge pressure (PAWP) > 15 mmHg. PAWP is a surrogate marker of left atrial pressure (LAP). An elevated LAP causing PH can occur in systolic and/or diastolic left ventricular (LV) dysfunction and in left-sided valvular disease. In the most recent clinical classification of PH (5) two additional etiologies of PH-LHD have been recognized: PH due to congenital or acquired left ventricular outflow tract...
obstruction and pulmonary vein stenosis. In the same guidelines, a new PH phenotype of “combined pre-capillary and post-capillary PH” (Cpc-PH) has been introduced on the grounds of a diastolic pressure gradient (DPG)—the difference between diastolic pulmonary arterial pressure and mean PAWP—equal or higher than 7 mmHg (Table 1). This new term came to replace the older “PH out of proportion to LHD.” Although, pathophysiology of Cpc-PH is not entirely clear, a chronic elevation of LAP due to longstanding LHD is believed to cause a profound pulmonary artery remodeling and pulmonary vascular resistance (PVR) rise, which is not usually found in isolated post-capillary PH. Patients with Cpc-PH seem to be in the middle of a spectrum of which pre-capillary PH and isolated post-capillary PH are the two extremes, regarding their clinical and echocardiographic characteristics (6). The prevalence of Cpc-PH amongst patients with systolic and diastolic heart failure is believed to be within 12 and 14% (7). An adequate understanding of pathophysiology along with an accurate diagnosis and differentiation of PH-LHD from pre-capillary PH, such as pulmonary arterial hypertension (PAH) and chronic thromboembolic PH (CTEPH), are of paramount importance to select the appropriate treatment for the patient.

**PATHOPHYSIOLOGY**

The pathophysiological hallmark of PH-LHD is elevated LAP. LV systolic and diastolic dysfunction as well as aortic and/or mitral valve stenosis and/or regurgitation can raise left ventricular filling pressure and subsequently LAP over a period of time. LAP can then be transmitted backwards via pulmonary veins to the pulmonary vasculature leading to pulmonary arterial intimal thickening and medial hypertrophy and PH (Figure 1). Compliance in the pulmonary vasculature, unlike in the systemic circulation, is more evenly distributed across the pulmonary bed and the distal vessels are responsible for most of it (8). Hence, compliance is mostly determined by PVR. The relationship between PVR and compliance is an inverse hyperbolic one. “Passive” left-sided elevated pressures shift the hyperbola leftwards leading to an additional decline of compliance for a given PVR and thus enhanced pulmonary wave reflections which return during ventricular systole and increase the systolic (but not the diastolic) pulmonary artery pressure (9). In a recent study, pulmonary arterial compliance (or capacitance) defined as the ratio of stroke volume to pulmonary pulse pressure was the best predictor of mortality in PH-LHD associated with heart failure with preserved left ventricular ejection fraction (HFpEF) (10).

**The Right Ventricle (RV)**

The first compensatory mechanism of the RV to the elevated pulmonary pressure is hypertrophy. Thus, the RV can adapt with a 4–to 5-fold increase in myocardial contractility, a process which is described pathophysiologically as right ventricular-pulmonary artery (RV-PA) “coupling.” In the next progressive stage the RV starts dilating, wall stress according to LaPlace’s law increases, imbalance between oxygen demand and supply and RV ischemia occurs, contractility declines, the RV fails to maintain cardiac output and inevitably “uncoupling” and decompensation begins. The development of tricuspid (TR) and pulmonary regurgitation due to annular dilatation leads to RV volume overload and decreases stroke volume even further. RV-PA coupling has been estimated by echocardiography as the ratio of tricuspid annular plane systolic excursion (TAPSE) to pulmonary artery systolic pressure (PASP) and a cut-off limit < 0.36 has been shown to have prognostic value (11). Coupling has also been estimated by a hybrid method combining RHC and cardiac magnetic resonance (CMR) as the ratio of pulmonary artery effective elastance, which is a measure of arterial load, to the maximum end-systolic RV elastance, which is an index of contractility (12).

Up until recently the impact of PH-LHD on RV function had been underestimated. In recent years, however, its significance and prognostic value has been highlighted. RV systolic dysfunction assessed by echocardiography has been found in at least 1/5 of patients with HFpEF and potentially up to 30–50% (13). In addition, a decrease of TAPSE by 5 mm was associated with a 26% mortality rise (13), while in another study a decrease of RV fractional area change by 7% with a 2.2-fold increase of all-cause mortality after adjustment for pulmonary pressures in patients with HFpEF (14).

**Ventricular Interdependence and Comorbidities**

Other parameters such as ventricular interdependence may contribute to decreased cardiac output and heart failure. As RV pressure increases and interventricular dysynchrony is established, the interventricular septum bows toward the LV moving “paradoxically” and leading to a decrease of LV diastolic filling and a further drop of stroke volume. In addition, atrial fibrillation, coronary artery disease via right coronary or circumflex artery stenosis leading to reduced RV oxygen supply, chronic obstructive pulmonary disease, obstructive sleep apnea, diabetes, and obesity, all comorbidities frequently seen in patients with LHD may increase pulmonary pressures and further compromise RV function.

**The Role of DPG**

DPG has been considered to be a more accurate indicator of pulmonary vascular remodeling in LHD than transpulmonary gradient (the difference between mean pulmonary artery pressure and mean PAWP [TPGI]), as it is theoretically not influenced
by the variability of cardiac output or the impact of LAP on pulmonary vascular compliance. In a retrospective large study in patients with PH-LHD an elevated $\mathrm{DPG} \geq 7 \text{ mmHg}$ was correlated with worse median survival compared with a $\mathrm{DPG} < 7 \text{ mmHg}$ and a high $\mathrm{TPG} > 12 \text{ mmHg}$ (15). In the same study, in a small number of patients high DPG was also correlated with greater pathological pulmonary vascular remodeling compared to patients with high TPG but normal DPG. Two further studies, retrospective as well, in patients who had undergone orthotopic heart transplantation and in patients with unexplained cardiomyopathy did not confirm the prognostic value of DPG (16, 17). In a more recent study the risk of death in Cpc-PH and isolated post-capillary PH after adjustment of relevant covariates was similar, however the researchers identified 75 common exonic single-nucleotide polymorphisms between Cpc-PH and pre-capillary PH in pathways pertinent with cell structure, extracellular matrix and immune function (6).
**DIAGNOSIS**

**Risk Factors, Clinical Symptoms, and Signs**

Features of metabolic syndrome such as obesity, systemic hypertension, diabetes and dyslipidemia, are more prevalent in patients with PH-LHD than PAH. Researchers have shown that two or more of these features were present in 94.1% of PH-LHD patients vs. only 34.3% of PAH (18). The findings were confirmed in another study, which showed that older age, the presence of systemic hypertension and coronary artery disease are more frequent in PH-LHD and can best differentiate from PAH along with other echocardiographic and hemodynamic parameters (19). In the same study there was a similarly high female predominance in the PH-LHD and PAH groups but more pronounced than in the HFpEF without PH group. In addition to these risk factors, the prevalence of permanent atrial fibrillation in PH-LHD seems to be significantly higher than in patients with PAH and risk factors for LHD (20).

The symptoms and clinical signs of patients with PH-LHD are those of heart failure. Exertional dyspnea, orthopnea, and/or paroxysmal nocturnal dyspnea, anginal chest pain typically on exertion, palpitations, dry cough, pre-syncpe and/or syncpe, hepatomegaly, ascites, elevated jugular venous pressure, and peripheral edema are the most common ones. Right ventricular heave, a loud pulmonary component of the second heart sound and a pansystolic murmur of tricuspid regurgitation may also be present. In a retrospective study which compared patients with PAH with or without cardiovascular comorbidities to PH-LHD, patients with PH-LHD were more likely to have peripheral edema, whilst there was a trend toward a worse functional class after adjustment for age but no difference in 6-min walking test distance (20). Patients with PH-LHD usually have normal resting oxygen saturations with a possible drop on exercise, unless if they also have respiratory comorbidity or a right-to-left shunt.

**Chest X-Ray, ECG, and Pulmonary Function Test**

The chest X-ray may show signs of cardiomegaly and enlarged pulmonary artery branches. Pleural effusions may be seen more frequently in PH-LHD than PAH, although they are not uncommon in severe PAH as well (21).

Left QRS axis deviation, atrial fibrillation and signs of left ventricular hypertrophy are more likely on ECG in PH-LHD than in pre-capillary PH, whereas right axis, sinus rhythm, R wave dominant in lead V1, ST-T segment depression, and T-wave inversion in the right precordial and inferior leads are more frequently seen in pre-capillary PH. Right bundle branch block does not appear to differentiate the two conditions (20, 22). These ECG findings have recently been incorporated in predictive score models to discriminate non-invasively between PH-LHD and PAH (23, 24).

It is well-known that pulmonary alveolar diffusion is impaired in patients with congestive heart failure. Gas transfer factor for carbon monoxide (TLco) is reduced in this population compared to controls (25). In addition, TLco and end-tidal CO₂ have been found to be lower in PAH patients compared to PH-LHD (26, 27).

In the ASPIRE registry, mean TLco in the PAH group was 55 vs. 62% predicted in the PH-LHD one (26).

**Natriuretic Peptides**

Brain natriuretic peptide (BNP) and its N-terminal fragment NT-proBNP can both be elevated in heart failure with reduced LV ejection fraction and HFpEF. They can be secreted from the cardiomyocytes of both ventricles due to stretching from volume overload. The upper limit of normal for BNP is 35 pg/mL and for NT-proBNP 125 pg/mL (28). Natriuretic peptides may be elevated in elderly people, atrial fibrillation and renal impairment without heart failure. They can also be disproportionately low in obese patients. In addition, they cannot differentiate between pre-capillary PH and PH-LHD as they may be raised in both conditions. Their role in patients’ follow-up, assessment of response to treatment and detection of progression of the underlying disease as well as their prognostic role can be very important.

**Echocardiography**

Echocardiography plays a seminal role in the detection of signs of PH-LHD. It can diagnose LV systolic and diastolic dysfunction, aortic and mitral valve disease, LV outflow tract obstruction, restrictive and hypertrophic cardiomyopathy and constrictive pericarditis. In all these conditions, LV diastolic dysfunction usually occurs and may lead to PH-LHD. The estimation of PASP, which raises the suspicion of PH when elevated, derives from applying continuous Doppler and the modified Bernoulli equation: 4 x peak TR velocity (TRV)² + estimated right atrial pressure. Right atrial pressure can be estimated from the size and collapsibility during respiration/sniff of the inferior vena cava on the subcostal view (29). According to the current ESC/ERS guidelines a threshold of peak TRV higher than 2.8 m/s is considered suspicious of PH with or without the presence of other echocardiographic signs of PH and risk factors for PH (5). However, peak TRV is angle and flow-dependent and it can frequently be underestimated (30). Peak TRV should be measured from several different acoustic windows and views, while in atrial fibrillation an average of measurements from the view with the highest velocities should be taken and only a well-defined, spade-shaped, dense spectral profile should be measured. In cases with no or trivial TR when TRV cannot accurately be estimated, mean pulmonary artery pressure can be calculated instead from the peak velocity of a pulmonary regurgitant jet at the beginning of diastole or from the acceleration time (time from onset to peak) of the forward flow at the right ventricular outflow tract (29).

Diagnosing LV diastolic dysfunction with echocardiography sometimes can be challenging. Four parameters have been recently included in an algorithm to determine diastolic dysfunction: an average (of septal and lateral) E/e’ > 14, a septal e’ < 7 cm/s or lateral <10 cm/s, a TRV > 2.8 m/s and a left atrial volume index >34 ml/m². If <50% of these parameters are present, diastolic function is normal, if >50%, there is diastolic dysfunction and when exactly 50%, diastolic function is indeterminate (31). Other echocardiographic signs such as mitral ‘L’ velocity >20 cm/s (ongoing LV filling in mid-diastole
due to markedly delayed LV relaxation), mitral inflow E/A wave velocity ratio and E wave deceleration time, as well as a higher diastolic wave velocity than the systolic one in the pulmonary vein Pulsed Doppler profile may also be useful (31). Unlike PH-LHD, significant LV diastolic dysfunction in PAH is very unlikely. In a small study, 88% of PAH patients demonstrated grade I (mild) diastolic dysfunction and 10% normal diastolic function (32).

Left atrial dilatation is considered to be one of the most useful indicators of LHD. However, in the presence of atrial fibrillation may not always represent elevated LAP. In atrial fibrillation, an average E/"e" >11 instead of 14 should be used as a marker of diastolic dysfunction (31). Researchers in the past have described conditions such as severe mitral regurgitation with a dilated left atrium but normal LAP. Left atrial compliance seems to play a pivotal role in these cases (33). The absence of mid-systolic “notching” in the right ventricular outflow tract Pulsed Doppler envelope has also been shown to be highly predictive of a PVR < 3 Wood units and a PAWP > 15 mmHg (34). On the other hand, a PASP > 70 mmHg is more likely to represent PAH than PH-LHD (35). The severity of TR cannot differentiate between PH-LHD and PAH. In a prospective cohort of patients with PAH and PH-LHD, 45% had mild, 34% moderate, and 21% severe TR. The mechanisms causing TR were annular dilatation, RV remodeling-tethering and inadequate tricuspid valve leaflet area (36). Finally, a RV end-diastolic diameter to LV end-diastolic diameter ratio (measured in the 4-chamber apical view at the tips of the atrioventricular valves) <1 and the absence of pericardial effusion seem to be more likely in PH-LHD than PAH (20). Table 2 summarizes the distinct echocardiographic characteristics in pre-capillary PH and PH-LHD. An echocardiographic score based on LA dimension, mid-systolic notching and E/"e" to differentiate between PH-LHD and PAH has been proposed (37). More recently another echocardiographic score, which seems to be useful in discriminating between isolated and Cpc-PH as well, has been published (38).

**CMR**

CMR may play an important role in making diagnosis and identifying prognosis of PH in general and PH-LHD in particular. Especially in cases where visualization or accuracy of measurements is limited, CMR should be strongly considered. CMR remains the gold standard imaging modality for RV measurements is limited, CMR should be strongly considered.

| TABLE 2 | Echocardiographic features likely to be present in pre- and post-capillary pulmonary hypertension. |
|----------|-------------------------------------------------------------------------------------------------|
| Pre-capillary PH | PH-LHD |
| Normal sized or small LV cavity | Normal sized or dilated LV cavity |
| No LV hypotrophy | LV hypotrophy |
| Preserved LVEF | Variable LVEF |
| Normal sized or small left atrium | Dilated left atrium |
| Grade I LV diastolic dysfunction or normal LV diastolic function | ≥ Grade II LV diastolic dysfunction |
| Presence of mid-systolic notching | Absence of mid-systolic notching |
| RV/LV ratio > 1 | RV/LV ratio < 1 |
| PASP > 70 mmHg | Typically PASP < 70 mmHg |
| Pericardial effusion | No pericardial effusion |
| No mitral and/or aortic valve disease | Mitral and/or aortic valve disease |

**Predictive Non-invasive Score Models**

Over the last few years, score models to assess the pre-RHC probability of PH-LHD have been created aspiring to avoid potentially unnecessary catheterizations. Bonderman et al. proposed a model based on RV strain on ECG and BNP (23). Jacobs et al. suggested a risk model including history of LHD, the sum of S deflection in V1 and R deflection in V6 on the ECG, left atrial dilatation and left valve disease worse than mild on echocardiogram (24). Finally, Richter et al. suggested a prediction score for elevated PAWP based on age >68 years, BMI > 30 kg/m², absence of RV enlargement and presence of left atrial dilatation on echocardiography (43).

**RHC-Fluid Challenge-Exercise-Vasoreactivity Testing**

The gold standard method for the diagnosis of PH-LHD remains RHC. All pulmonary pressures should be measured at end-expiration with the patient breathing spontaneously. The mean PAWP has been better correlated with mean LAP than the LV end-diastolic pressure (LVEDP) in patients with LV disease, except for very high PAWP over 25 mmHg (44, 45). However, a LVEDP > 15 mmHg on left heart catheterization can be used to define PH-LHD, when an accurate PAWP is not feasible (e.g., in chronic thromboembolic disease). An accurate PAWP may be challenging to obtain. A waveform consistent with atrial waveform, a PAWP ≤ diastolic pulmonary arterial pressure, blood easily aspirated and highly oxygenated in the wedge position and the placement of the tip of the catheter in West zone 3 (at the lung base, where pulmonary artery and venous pressure exceeds pulmonary alveolar pressure, which represents lung areas with the greatest blood flow rates), below left atrial level, can eliminate technical difficulties. Mitral regurgitation may cause large “v” waves that can be mistakenly interpreted as an elevated PAWP. This can be accounted for by reading the PAWP at the
time of the “a” wave. Patients with PH-LHD tend to have a higher mean right atrial pressure, cardiac output and right ventricular end-diastolic pressure, as well as lower PVR compared with PAH (19, 20).

Patients with clinical and echocardiographic features suggestive of PH-LHD may sometimes have pre-capillary PH, especially if they have been previously heavily diuresed. Fluid challenge, which is the rapid intravenous administration of a high volume of occult saline, is believed to be helpful to unpick cases of occult PH-LHD with resting pre-capillary hemodynamics and unmask LV diastolic dysfunction. The current ESC/ERS PH guidelines do not recommend fluid loading at RHC due to lack of standardization as well as the theoretical risk of a rapid significant PAWP elevation to result in pulmonary edema. Three studies with fluid challenge in PH patients have been conducted since the publication of these guidelines though. In the first one, the infusion of 500 mL of saline within 5–10 min led to the reclassification of 22.2% of patients as occult PH-LHD (defined as a mean PAWP > 15 mmHg), while in another small study in patients with systemic sclerosis a similar percentage of patients with pre-capillary baseline hemodynamics were found to have a LVEDP > 15 mmHg post-infusion of 500 mL within 5–10 min (46, 47). In the most recent one, rapid infusion of saline at a rate of 7 mL/kg reclassified 8% of patients with no PH and 6% of patients with pre-capillary PH at baseline. A cut-off limit of PAWP ≥ 18 mmHg was used in the latter study (48). In all three studies, fluid loading was safe. Of note, even in healthy subjects a rapid fluid infusion will lead to a PAWP > 15 mmHg in a percentage >60%, however with a larger than 500 mL volume of saline (49). Likewise, exercise during RHC may unmask diastolic dysfunction in patients with suspected HFpEF and a baseline PAWP < 15 mmHg. Exercise can be performed on a supine or upright bike (the latter would be feasible when the RHC is done from the neck or the arm) or with leg lifting. In normal subjects and athletes, an increase of PAWP up to 25 mmHg in a broadly linear fashion with cardiac output has been shown (50). However, significant increases of PAWP at a cardiac output < 10 L/min is uncommon in normal individuals. Exercise during RHC seems to be particularly helpful in obese patients with a borderline, between 12 and 15 mmHg, PAWP (51).

According to the ESC/ERS guidelines vasoreactivity testing is only recommended in patients with suspected idiopathic, familial, or drug-induced PAH (5). In the context of PH-LHD vasodilator challenge can be used in the evaluation of patients for listing for cardiac transplantation, especially those with a TPG > 12–15 mmHg and/or PVR > 3 Wood units. The preferable vasodilator agent is inhaled nitric oxide. An increase of PAWP post-nitric oxide may be seen but pulmonary edema is very rare.

**Treatment**

PAH targeted therapies act on three distinct pathophysiological pathways. The first one is the nitric oxide-soluble guanylate cyclase (sGC)-cGMP pathway which includes drugs like phosphodiesterase type 5 inhibitors (Sildenafil, Tadalafil) and stimulators of cGMP like Riociguat. The second one is the endothelin-1 pathway with drugs like endothelin receptor antagonists (Bosentan, Ambrisentan, and Macitentan) and the third is the prostacyclin pathway with prostacyclins analogs (Epoprostenol, Treprostinil, Iloprost) and an oral selective IP prostacyclin-receptor agonist (Selexipag). These drugs have proven to be efficacious in PAH and CTEPH patients in several randomized, controlled, double-blind trials. On the other hand, trials of the same drugs in patients with PH-LHD have not shown any benefit and some of them have also been related with increased mortality (52–54). In the recent SIOVAC trial (55), where Sildenafil was tested vs. placebo in patients with post-capillary PH and history of correction of valvular heart disease, median PVR in the Sildenafil group was 3.4 Wood units, TPG 16 mmHg, but DPG only 2 mmHg. Of note, the study did not meet its primary end-point. Further trials need to be conducted in patients with Cpc-PH hemodynamics to answer the question about a possible efficacy of pulmonary vasodilator drugs in this specific PH phenotype.

**CONCLUSIONS**

Up to now, no pulmonary vasodilator treatment has proven to be efficacious in PH-LHD. Some of the PAH drugs have even been detrimental when given in patients with LHD. Hence, it is apparent that the accurate identification of the major driver of PH in each patient is essential. In clinical practice the diagnosis and phenotyping of PH cannot be based on a single test, even if that test is the RHC, but rather on a combination of clinical data, imaging and hemodynamics. A better understanding of pathophysiology and further clinical trials are required to clarify whether Cpc-PH is a distinct clinical entity or part of a spectrum of PH phenotypes and identify potential treatments for the future.

**AUTHOR CONTRIBUTIONS**

All authors listed have made a substantial, direct and intellectual contribution to the work, and approved it for publication.

**REFERENCES**

1. Lam CS, Roger VL, Borlaug BA, Enders FT, Redfield MM. Pulmonary hypertension in heart failure with preserved ejection fraction: a community-based study. *J Am Coll Cardiol.* (2009) 53:1119–26. doi: 10.1016/j.jacc.2008.11.051

2. Leung CC, Moondra V, Catherwood E, Andrus BW. Prevalence and risk factors of pulmonary hypertension in patients with elevated pulmonary venous pressure and preserved ejection fraction. *Am J Cardiol.* (2010) 106:284–6. doi: 10.1016/j.amjcard.2010.02.039

3. Damy T, Goode KM, Kallvikbacka-Bennett A, Lewinter C, Hobkirik J, Nikitin NP, et al. Determinants and prognostic value of pulmonary arterial hypertension in patients with chronic heart failure. *Eur Heart J.* (2010) 31:2280–90. doi: 10.1093/eurheartj/ehq245
patients with pulmonary arterial hypertension and cardiovascular risk factors. *Palm Circ.* (2014) 4:669–78. doi: 10.1086/678512

21. Milne EN. Forgotten gold in diagnosing pulmonary hypertension: the plain chest radiograph. *Radiographics* (2012) 32:1085–7. doi: 10.1148/rg.324125021

22. McMurray JJ, Carson PE, Komajda M, McKelvie R, Zile MR, Pratsunova A, et al. Heart failure with preserved ejection fraction: clinical characteristics of 4133 patients enrolled in the I-PRESERVE trial. *Eur J Heart Fail.* (2008) 10:149–56. doi: 10.1016/j.ejheart.2007.12.010

23. Bonderman D, Wexberg P, Martischamig AM, Heinzl H, Lang MB, Saduschi R, et al. A noninvasive algorithm to exclude pre-capillary pulmonary hypertension. *Eur Respir J.* (2011) 37:1096–103. doi: 10.1183/09031936.00089610

24. Jacobs W, Konings TC, Heymans MW, Boonstra A, Bogaard HJ, van Rossum AC, et al. Noninvasive identification of left-sided heart failure in a population suspected of pulmonary arterial hypertension. *Eur Respir J.* (2015) 46:422–30. doi: 10.1183/09031936.00202814

25. Smith AA, Cowburn PJ, Parker ME, Denvir M, Puri S, Patel KR, et al. Impaired pulmonary diffusion during exercise in patients with chronic heart failure. *Circulation* (1999) 100:1406–10.

26. Hurdman D, Condillie R, Elliot CA, Davies C, Hill C, Wild JM, et al. ASPIRE registry: assessing the Spectrum of Pulmonary hypertension Identified at a referral centre. *Eur Respir J.* (2012) 39:945–55. doi: 10.1183/09031936.00087411

27. Hennes AR, Pugh ME, Newman AL, Robbins IM, Tolle J, Austin ED, et al. End tidal CO2 tension: pulmonary arterial hypertension vs pulmonary venous hypertension and response to treatment. *Chest* (2011) 140:1267–73. doi: 10.1378/chest.11-0155

28. Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JGF, Coates AJS, et al. Assessment of pulmonary hypertension: a report from the American society of echocardiography endorsed by the European association of echocardiography. *Circulation* (2010) 23:685–713. doi: 10.1161/CIR.0b013e3181d50530

29. Fisher MR, Forfia PR, Chamera E, Houston-Harris T, Champion HC, Girgis RE, et al. Accuracy of Doppler echocardiography in the hemodynamic assessment of pulmonary hypertension. *Am J Respir Crit Care Med.* (2009) 179:615–21. doi: 10.1164/rccm.200811-1690OC

30. Nagueh SF, Smiseth OA, Appleton CP, Muhlbaier LH, Asnani P, et al. Recommendations for the evaluation of left ventricular diastolic function by echocardiography: an update from the American Society of Echocardiography and the American Association for Cardiovascular Imaging. *Eur Heart J Cardiovasc Imaging* (2016) 17:1321–60. doi: 10.1093/ehjci/ehw015

31. Tonelli AR, Plana JC, Heresi GA, Dweik RA. Prevalence and prognostic value of the pre-transplant diastolic pulmonary artery pressure-to-pulmonary capillary wedge pressure gradient in cardiac transplant recipients with pulmonary hypertension. *J Heart Lung Transplant* (2014) 33:289–197. doi: 10.1016/j.healun.2013.11.008

32. Robbins IM, Newman JH, Johnson RF, Hennes AR, Fremont RD, Plana RN, et al. Association of the metabolic syndrome with pulmonary venous hypertension. *Chest* (2009) 136:31–6. doi: 10.1378/chest.08-2008

33. Themanann T, Shah SJ, Gomberg-Maitland M, Collander B, Vallakati A, Shroff P, et al. Clinical characteristics of pulmonary hypertension in patients with heart failure and preserved ejection fraction. *Circ Heart Fail* (2011) 4:257–65. doi: 10.1161/CIRCHARTFAILURE.110.958801

34. Charalampopoulos A, Howard LS, Tzoulaki I, Gin-Sing W, Grapa J, Wilkins MR, et al. Response to pulmonary arterial hypertension drug therapies in
38. D’Alto M, Romeo E, Argiento P, Pavelescu A, D’Andrea A, Di Marco GM, et al. A simple echocardiographic score for the diagnosis of pulmonary vascular disease in heart failure. J Cardiovasc Med. (2017) 18:237–43. doi: 10.2459/JCM.000000000000485
39. Mooij CF, de Wit CJ, Graham DA, Powell AJ, Geva T. Reproducibility of MRI measurements of right ventricular size and function in patients with normal and dilated ventricles. J Magn Reson Imaging (2008) 28:67–73. doi: 10.1002/jmri.21407
40. Marcus JT, Vonk Noordegraaf A, Roeleveld RJ, Heethaar RM, Van Rossum AC, et al. Impaired left ventricular filling due to right ventricular pressure overload in primary pulmonary hypertension: noninvasive monitoring using MRI. Chest (2001) 119:1761–5
41. Sanz J, Kariisa M, Dellegrottaglie S, Prat-González S, Garcia MJ, Fuster V, et al. Evaluation of pulmonary artery stiffness in pulmonary hypertension with cardiac magnetic resonance. JACC Cardiovasc Imaging (2009) 2:286–95. doi: 10.1016/j.jcmg.2008.08.007
42. Swift AJ, Rajaram S, Condliffe R, Capener D, Hurdman J, Elliot CA, et al. Diagnostic accuracy of cardiovascular magnetic resonance imaging of right ventricular morphology and function in the assessment of suspected pulmonary hypertension results from the ASPIRE registry. J Cardiovasc Magn Reson. (2012) 14:40. doi: 10.1186/1532-429X-14-40
43. Richter SE, Roberts KE, Preston IR, Hill NS. A simple derived prediction score for the identification of an elevated pulmonary artery wedge pressure using precatheterization clinical data in patients referred to a Pulmonary Hypertension center. Chest (2016) 149:1261–8. doi: 10.1378/chest.15-0819
44. Braunwald E, Shab-i, Braunwald E. Does results of the ENABLE (Endothelin Antagonist Bosentan for Lowering Cardiac Events in Heart Failure) spell the end for non-selective endothelin antagonism in heart failure? Int J Cardiol. (2002) 85:195–97. doi: 10.1016/S0167-5273(02)00182-1
45. Bozic HM, Zhigang M, Zhong M, et al. A randomized controlled trial of epoprostenol therapy for severe congestive heart failure: The Flolan International Randomized Survival Trial (FIRST). Am J Heart J. (1997) 134:44–54.
46. Kala PA, Moon JC, Coats AJ. Do results of the ENABLE (Endothelin Antagonist Bosentan for Lowering Cardiac Events in Heart Failure) spell the end for non-selective endothelin antagonism in heart failure? Int J Cardiol. (2002) 85:195–97. doi: 10.1016/S0167-5273(02)00182-1
47. Bonderman D, Ghio S, Felix SB, Ghofrani HA, Michelakis E, Mitrovic V, et al. Riociguat for patients with pulmonary hypertension caused by systolic left ventricular dysfunction: a phase IIb double-blind, randomized, placebo-controlled, dose-ranging hemodynamic study. Circulation (2013) 128:502–11. doi: 10.1161/CIRCULATIONAHA.113.01458
48. Bermejo J, Yotti R, Garcia-Orta R, Sánchez-Fernández PL, Castaño M, Segovia-Cubero J, et al. Sildenafil for improving outcomes in patients with corrected valvular heart disease and persistent pulmonary hypertension: a multicenter, double-blind, randomized, controlled trial. Eur Heart J. (2018) 39:1255–64. doi: 10.1093/eurheartj/ehx700

Conflict of Interest Statement: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2018 Charalampopoulos, Lewis, Hickey, Durrington, Elliot, Condliffe, Sabroe and Kiyi. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.